Douglas Lane & Associates’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.51M | Buy |
9,961
+436
| +5% | +$93.8K | 0.03% | 146 |
|
|
2026
Q1 | $2.07M | Sell |
9,525
-96
| -1% | -$21.3K | 0.03% | 144 |
|
|
2025
Q4 | $2.2M | Sell |
9,621
-365
| -4% | -$83.1K | 0.03% | 142 |
|
|
2025
Q3 | $2.31M | Sell |
9,986
-349
| -3% | -$71.1K | 0.03% | 141 |
|
|
2025
Q2 | $1.92M | Buy |
10,335
+29
| +0.3% | +$5.39K | 0.03% | 142 |
|
|
2025
Q1 | $2.16M | Sell |
10,306
-338
| -3% | -$65.7K | 0.03% | 141 |
|
|
2024
Q4 | $1.89M | Buy |
10,644
+23
| +0.2% | +$4.23K | 0.03% | 145 |
|
|
2024
Q3 | $2.1M | Sell |
10,621
-475
| -4% | -$88.7K | 0.03% | 144 |
|
|
2024
Q2 | $1.9M | Sell |
11,096
-515
| -4% | -$85.3K | 0.03% | 143 |
|
|
2024
Q1 | $2.11M | Sell |
11,611
-373
| -3% | -$64.3K | 0.03% | 142 |
|
|
2023
Q4 | $1.86M | Sell |
11,984
-1,412
| -11% | -$206K | 0.03% | 142 |
|
|
2023
Q3 | $2M | Buy |
13,396
+979
| +8% | +$144K | 0.03% | 132 |
|
|
2023
Q2 | $1.67M | Buy |
12,417
+262
| +2% | +$38.4K | 0.03% | 138 |
|
|
2023
Q1 | $1.94M | Sell |
12,155
-715
| -6% | -$109K | 0.03% | 135 |
|
|
2022
Q4 | $2.08M | Sell |
12,870
-1,140
| -8% | -$175K | 0.03% | 135 |
|
|
2022
Q3 | $1.88M | Buy |
14,010
+403
| +3% | +$57.8K | 0.03% | 132 |
|
|
2022
Q2 | $2.08M | Sell |
13,607
-79
| -0.6% | -$12.1K | 0.04% | 133 |
|
|
2022
Q1 | $2.22M | Sell |
13,686
-216
| -2% | -$31.4K | 0.03% | 136 |
|
|
2021
Q4 | $1.88M | Buy |
13,902
+349
| +3% | +$41.2K | 0.03% | 145 |
|
|
2021
Q3 | $1.46M | Sell |
13,553
-88
| -0.6% | -$10.1K | 0.02% | 146 |
|
|
2021
Q2 | $1.54M | Buy |
13,641
+1,852
| +16% | +$209K | 0.02% | 145 |
|
|
2021
Q1 | $1.28M | Buy |
11,789
+651
| +6% | +$69.6K | 0.02% | 143 |
|
|
2020
Q4 | $1.19M | Buy |
11,138
+673
| +6% | +$64.7K | 0.02% | 139 |
|
|
2020
Q3 | $917K | Sell |
10,465
-622
| -6% | -$58.6K | 0.02% | 141 |
|
|
2020
Q2 | $1.09M | Sell |
11,087
-340
| -3% | -$29.9K | 0.02% | 137 |
|
|
2020
Q1 | $871K | Sell |
11,427
-1,324
| -10% | -$113K | 0.02% | 140 |
|
|
2019
Q4 | $1.13M | Sell |
12,751
-485
| -4% | -$40.3K | 0.02% | 144 |
|
|
2019
Q3 | $1M | Sell |
13,236
-662
| -5% | -$45.4K | 0.02% | 143 |
|
|
2019
Q2 | $1.01M | Sell |
13,898
-2,250
| -14% | -$177K | 0.02% | 148 |
|
|
2019
Q1 | $1.3M | Sell |
16,148
-18
| -0.1% | -$1.47K | 0.03% | 140 |
|
|
2018
Q4 | $1.49M | Sell |
16,166
-300
| -2% | -$26.4K | 0.04% | 133 |
|
|
2018
Q3 | $1.56M | Buy |
16,466
+574
| +4% | +$54.4K | 0.03% | 137 |
|
|
2018
Q2 | $1.47M | Sell |
15,892
-539
| -3% | -$52.6K | 0.03% | 134 |
|
|
2018
Q1 | $1.55M | Sell |
16,431
-875
| -5% | -$96.1K | 0.03% | 132 |
|
|
2017
Q4 | $1.67M | Buy |
17,306
+426
| +3% | +$40.1K | 0.04% | 130 |
|
|
2017
Q3 | $1.5M | Sell |
16,880
-475
| -3% | -$36.2K | 0.03% | 132 |
|
|
2017
Q2 | $1.26M | Sell |
17,355
-931
| -5% | -$62.6K | 0.03% | 142 |
|
|
2017
Q1 | $1.19M | Sell |
18,286
-1,043
| -5% | -$65.6K | 0.03% | 147 |
|
|
2016
Q4 | $1.21M | Sell |
19,329
-1,073
| -5% | -$65.5K | 0.03% | 146 |
|
|
2016
Q3 | $1.29M | Sell |
20,402
-2,319
| -10% | -$150K | 0.03% | 147 |
|
|
2016
Q2 | $1.41M | Buy |
22,721
+1,121
| +5% | +$68.3K | 0.04% | 147 |
|
|
2016
Q1 | $1.23M | Buy |
+21,600
| New | +$1.2M | 0.03% | 149 |
|
Other funds holding ABBV
Douglas Lane & Associates's ABBV Position: Q2 2026 in Review
Douglas Lane & Associates increased its AbbVie (ABBV) stake by 4.6% in Q2 2026, buying an estimated $93.8K and bringing the position to 9,961 shares worth $2.51M. The position accounts for 0.03% of the portfolio, ranked #146.
Douglas Lane & Associates first reported a position in ABBV in Q1 2016 and has held it in 42 quarters since. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Douglas Lane & Associates held 9,961 shares of AbbVie worth $2.51M as of Q2 2026.
- Douglas Lane & Associates bought 436 AbbVie shares in Q2 2026, an estimated $93.8K.
- AbbVie made up 0.03% of Douglas Lane & Associates's portfolio in Q2 2026, its #146 holding.
- Douglas Lane & Associates first reported a position in AbbVie in Q1 2016 and has held it in 42 quarters since.
- 4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Douglas Lane & Associates's 13F filing for Q2 2026, filed 14 Jul 2026.